PDF Cover

Biodegradable Vascular Stents Market

The market for Biodegradable Vascular Stents was estimated at $362 million in 2025; it is anticipated to increase to $650 million by 2030, with projections indicating growth to around $1.17 billion by 2035.

Report ID:DS1801597
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Biodegradable Vascular Stents
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Biodegradable Vascular Stents Market Outlook

Revenue, 2025

$362M

Forecast, 2035

$1.17B

CAGR, 2026 - 2035

12.4%

The Biodegradable Vascular Stents (BVS) industry revenue is expected to be around $407.3 million in 2026 and expected to showcase growth with 12.4% CAGR between 2026 and 2035. Building on this growth trajectory, the biodegradable vascular stents market is gaining strong clinical and commercial traction due to the rising global burden of cardiovascular diseases and the growing preference for minimally invasive interventions. Increasing awareness among healthcare providers regarding long-term complications associated with permanent metallic stents is accelerating the shift toward bioresorbable alternatives. In addition, favorable regulatory support, ongoing clinical trials, and advancements in polymer science are enhancing product reliability and safety profiles. Healthcare systems are also focusing on reducing repeat interventions and improving patient outcomes, which further strengthens demand. Strategic collaborations between medical device manufacturers and research institutions, along with expanding adoption in emerging markets, continue to reinforce the market’s relevance and position within interventional cardiology.

Biodegradable vascular stents, also known as bioresorbable stents, are advanced medical devices designed to provide temporary scaffolding to narrowed or blocked arteries and gradually dissolve within the body over time. These stents are primarily made from biodegradable polymers or magnesium-based alloys, eliminating the need for long-term implantation and reducing risks such as late-stage thrombosis or chronic inflammation. They are widely used in coronary artery disease treatment, particularly in percutaneous coronary interventions, where restoring blood flow efficiently is critical. Recent innovations focus on improving radial strength, controlled degradation rates, and drug-eluting capabilities to enhance therapeutic outcomes. Growing emphasis on patient-centric care, combined with increasing investments in next-generation stent technologies and expanding applications in peripheral artery diseases, is significantly driving the adoption of BVS across global healthcare systems.

Biodegradable Vascular Stents market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Biodegradable Vascular Stents Market Outlook

Market Key Insights

  • The Biodegradable Vascular Stents market is projected to grow from $362.4 million in 2025 to $1.17 billion in 2035. This represents a CAGR of 12.4%, reflecting rising demand across Coronary artery disease and Peripheral artery disease.

  • Abbott, BIOTRONIK, Elixir Medical are among the leading players in this market, shaping its competitive landscape.

  • U.S. and China are the top markets within the Biodegradable Vascular Stents market and are expected to observe the growth CAGR of 11.2% to 14.9% between 2025 and 2030.

  • Emerging markets including Indonesia, Brazil and Indonesia are expected to observe highest growth with CAGR ranging between 8.7% to 13.0%.

  • Transition like Vessel Restoration via Bioresorbable Platforms is expected to add $66 million to the Biodegradable Vascular Stents market growth by 2030.

  • The Biodegradable Vascular Stents market is set to add $804 million between 2025 and 2035, with manufacturer targeting Peripheral interventions & Carotid interventions Application projected to gain a larger market share.

  • With

    rising complex coronary and peripheral lesions and value based care pressures accelerate biodegradable vascular stent adoption, and

    Advanced bioresorbable polymers and magnesium alloys improve BDS performance, Biodegradable Vascular Stents market to expand 222% between 2025 and 2035.

biodegradable vascular stents market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Biodegradable Vascular Stents - Country Share Analysis

Opportunities in the Biodegradable Vascular Stents

Public hospitals choose technologies that decrease repeat procedures and downstream costs because CONITEC evaluations prioritize value. Bioresorbable coronary scaffolds provide future surgical possibilities while preventing metal related complications that last long term which matches SUS quality standards. The Southeast and Northeast corridors will also experience the fastest growth in sirolimus eluting PLLA coronary scaffold adoption because of ANVISA registrations and optimized tenders with regional distributors and multicenter outcomes studies that enhance cost effectiveness dossiers.

Growth Opportunities in North America and Asia-Pacific

The market for biodegradable vascular stents expands because of a mature interventional cardiology ecosystem combined with high coronary artery disease prevalence and hospital requirements for innovative devices that reduce long term restenosis risk. The market opportunities exist in next generation bioresorbable scaffolds with thinner struts and magnesium alloys and improved deliverability for complex lesions and peripheral vascular disease indications. The FDA Breakthrough designations together with real world registries drive evidence development while consolidated hospital purchasing and GPOs need strong healtheconomic data. The competitive landscape consists of global leaders and venture backed startups who continue to improve PLLA and magnesium designs through strategic partnerships and physician training and KOL led trials which drive adoption.
The region will experience above average bioresorbable stent adoption because of fast PCI growth and positive demographics and increasing catheterization lab capacity especially in region's with challenging lifetime dual antiplatelet therapy requirements. The market offers three main opportunities which include local manufacturing and value engineered platforms for tender markets and magnesium or PLLA devices designed for Asian anatomies small vessels. The Japan PMDA and China NMPA regulatory momentum together with HTA pathways in Australia and South Korea facilitate market entry but reimbursement variability continues to exist. The market faces intense competition because domestic champions and multinational OEMs fight for market share through clinical evidence and distribution depth and physician education programs.

Market Dynamics and Supply Chain

01

Driver: Rising complex coronary and peripheral lesions and value based care pressures accelerate biodegradable vascular stent adoption

The increasing number of long calcified and small vessel lesions in diabetic and peripheral artery disease patients leads interventionalists to choose temporary scaffolds which promote endothelial healing and restore vasomotion and decrease late stent thrombosis; also advances in ultrathin struts and optimized sirolimus elution and OCT/IVUS guided sizing improve performance in these anatomies. Third, value based care and bundled payments reward fewer repeat procedures and lower lifetime costs; healtheconomic models and real world registries indicate bioresorbable stents can also cut target lesion revascularization beyond year two, strengthening hospital procurement cases and payer coverage rationales.
The development of new materials has also led to the creation of scaffolds that degrade at specific rates while becoming easier to deliver. Stereocomplex PLLA and tyrosinederived polycarbonates provide radial strength and reduced inflammation while maintaining drug release profiles that support consistent late lumen gain. Rareearth magnesium alloys with grain refinement and surface passivation through microarc oxidation techniques slow down corrosion to maintain mechanical stability during healing processes. The technological advancements allow for thinner strut designs which reduce thrombogenicity and improve crossing profiles thus expanding treatment possibilities and strengthening medical professional trust in future bioresorbable vascular scaffolds.
02

Restraint: Clinical safety concerns and evidence gaps

The thicker struts of BVS continue to raise concerns about late scaffold thrombosis and restenosis risk and deliverability in complex lesions which reduce cardiologist confidence and slow down procedural adoption. The combination of increased regulatory oversight and past notable product recalls has led to stricter trial requirements and longer approval processes that result in conservative guidelines and hospital value analysis committee decisions. The reimbursement policies of payers restrict coverage to specific patient groups while demanding registry data which restricts standard use of these devices and maintains their usage below drug eluting stent levels. The current market situation extends the time until demand peaks while decreasing tender success rates which drives procurement toward established metallic DES systems in major treatment centers.
03

Opportunity: Endovascular interventions for diabetic peripheral artery disease patients in Indias tier two cities and High risk elderly cardiac patients in Japan requiring temporary vessel support during PCI

The increasing diabetes cases in India together with late PAD diagnosis create a growing need for below the knee revascularization procedures in underserved tier two cities. The biodegradable scaffolds maintain vessel patency through their ability to dissolve without creating permanent metal structures that would make future procedures more complicated. The market will experience its highest expansion through magnesium based bioresorbable peripheral stents used for tibial and peroneal vessels because of Ayushman Bharat coverage and CDSCO approvals and cath lab partnerships and training programs that decrease hesitancy and create standardized procedures.
The aging population of Japan along with its high bleeding risk profiles force cardiologists to reduce dual antiplatelet exposure while maintaining future treatment options. Bioresorbable stents function as temporary support devices which restore vessel health through long term processes when used with IVUS/OCT imaging systems. The strongest adoption of thin strut sirolimus eluting bioresorbable coronary scaffolds will occur in university and flagship hospitals through MHLW reimbursement categories and trials with imaging leaders and rigorous post market registries.
04

Challenge: Cost, reimbursement, and competitive pressure

The combination of high device expenses with premium DES and the requirement for OCT/IVUS guidance and extended procedure duration creates episode of care expenses which value based purchasing models struggle to support. The reimbursement systems across markets show inconsistent patterns while payers need long term results to prove cost effectiveness which results in limited coverage and selective hospital formulary adoption. Bioresorbable stents usually end up in specific indications or young low risk patients during competitive tenders because procurement teams select the lowest total cost and most predictable outcomes which reduces the immediate market potential. The price sensitivity in emerging markets together with established DES performance advantages create adoption curves that are compressed and reduce near term demand growth.

Supply Chain Landscape

1

Biomaterials Supply

EvonikCorbionLuxfer MEL Technologies
2

Device Manufacturing

BiotronikMeril Life SciencesAbbott Vascular
3

Sterilization & Packaging

STERIS ASTSterigenicsDuPont
4

Distribution & Clinical Use

Cardinal HealthOwens & MinorCardiac Catheterization Labs
Biodegradable Vascular Stents - Supply Chain

Use Cases of Biodegradable Vascular Stents in Coronary artery disease & Peripheral artery disease

Coronary artery disease : The deployment of drug eluting bioresorbable vascular scaffolds BRS through standard percutaneous coronary intervention creates scaffolds for de novo coronary lesions which then dissolve over time. The treatment method enables vasomotion recovery while reducing the chance of very late stent thrombosis and maintains future bypass and imaging capabilities through its metal free design. The Magmaris CE marked product from BIOTRONIK stands as the market leader while Merils Me Res100 provides thin strut everolimus delivery, value positioning, Abbott brings global scale and next generation research & development capabilities.
Peripheral artery disease : The endovascular delivery of drug-eluting bioresorbable scaffolds for peripheral artery disease uses biodegradable polymers such as PLLA platforms and emerging magnesium designs to support femoropopliteal or below-the-knee vessels after angioplasty. These temporary scaffolding systems reduce chronic metal fatigue and fracture, while allowing natural vessel remodeling and preserving options for future bypass or repeat interventions. Abbott continues to advance the Esprit BTK program through its extensive clinical infrastructure, REVA Medical’s Motiv sirolimus BRS benefits from FDA Breakthrough status and polymer expertise, and Meril is gaining momentum in cost-sensitive markets.

Impact of Industry Transitions on the Biodegradable Vascular Stents Market

As a core segment of the Medical Device industry, the Biodegradable Vascular Stents market develops in line with broader industry shifts. Over recent years, transitions such as Vessel Restoration via Bioresorbable Platforms and OutcomeDriven Evidence and ValueBased Uptake have redefined priorities across the Medical Device sector, influencing how the Biodegradable Vascular Stents market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Vessel Restoration via Bioresorbable Platforms

The market transition from permanent metal scaffolds to resorbable drug eluting systems made from PLLA and magnesium occurs because BVS restore natural vasomotion after controlled degradation. The market transformation requires manufacturing to adopt precision extrusion and lasercutting and biaxial orientation and GMP/ISO 13485 polymer supply chains to reduce thrombosis risk and enhance outcomes. A specialty biopolymer supplier that produces medical grade PLLA has secured multiple year contracts for coronary stents and resorbable orthopedic screws which drives industry wide adoption and unified quality standards.
02

OutcomeDriven Evidence and ValueBased Uptake

The development of bioresorbable scaffolds has led to a shift in adoption toward realworld evidence and AIassisted intravascular imaging and riskstratified patient selection which aligns with valuebased care and outcomesbased contracts. The regulatory focus now centers on strong PMCF and registries and extended followup periods because of FDA Breakthrough and EU MDR requirements which drives analytics vendors and hospital cathlab systems to implement longitudinal tracking capabilities. A national payers pilot program for reimbursement based on late lumen patency and reduced repeat PCI has motivated health IT firms to develop crossdevice registries which structural heart programs also utilize.